Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.
Overview
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) is a phase 3 interventional study registered as NCT06088290 by PharmaMar, with 469 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2029-08-30. Interventions recorded: Lurbinectedin and Doxorubicin.
Similar pages
not linked directly; found by shared links- TrialStudy of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Shares PharmaMar and the tag pipeline.
- TrialPlacebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Shares Doxorubicin and the tag pipeline.
- TrialSTC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Shares Uterine sarcoma and the tag pipeline.
- TrialA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Shares Uterine sarcoma and the tag pipeline.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares Doxorubicin and the tag pipeline.
- TrialBlood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
Shares Doxorubicin and the tag pipeline.
- TrialBlood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
Shares Doxorubicin and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Shares Doxorubicin and the tag pipeline.